The Effect of Probiotics ATG-F4 in Cancer Patients

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

Patients with advanced colorectal cancer or pancreatic cancer who are receiving oxaliplatin-based chemotherapy will be included. The research participants in this study will consume probiotics along with safety and anti-cancer agent side effect-related questionnaires, blood, and fecal sample collection for up to 12 weeks from the date of registration. The total duration of participation for research subjects is 12 weeks.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 19
Healthy Volunteers: f
View:

• Patients diagnosed with advanced colorectal cancer or pancreatic cancer who are undergoing treatment with Oxaliplatin-based chemotherapy at Chungnam National University Hospital, including both newly diagnosed and recurrent cases.

• Aged 19 years or older.

• Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2 points.

• Expected life expectancy of at least 3 months.

• Ability to understand the requirements of the clinical trial and willingness to sign the informed consent form.

Locations
Other Locations
Republic of Korea
Chungnam National University Hospital
RECRUITING
Daejeon
Contact Information
Primary
Hyewon Ryu, Professor
ryhw001@naver.com
82 + 42 280 6834
Backup
Sora Kang, clinical professor
sorakang0515@gmail.com
Time Frame
Start Date: 2024-03-01
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 30
Treatments
Experimental: LT-002 (Lactobacillus reuteri ATG-F4) arm
The group that will be consuming probiotics (LT-002 (Lactobacillus reuteri ATG-F4)) for 12 weeks. The subjects will take a daily intake of 4 x 10\^10 colony forming unit (CFU) of LT-002.
Related Therapeutic Areas
Sponsors
Leads: Chungnam National University Hospital
Collaborators: AtoGen Co. Ltd

This content was sourced from clinicaltrials.gov